Evgen Pharma ready to prove broccoli drug's worth
Can a humble molecule with a heritage in broccoli really cure any number of ailments?
That’s the premise behind Evgen Pharma (LON:EVG) and chief executive Stephen Franklin says that after eight years of development work, the company has arrived at the business end of proving it.
A phase II trial for the molecule, sulforaphane, as a treatment for a rare form of stroke has just got underway, while the company also has the funds for a breast cancer trial.
Results due in 2018 and Franklin says all investors have to do until then is hold their nerve.
Meet W Resources PLC, Avation PLC, Anglo Asian Mining PLC and Salt Lake Potash Ltd at our event,
London , 28 February 2019.
Register here »